Our investment solutions give institutional and qualified investors access to unlisted infrastructure investments in Switzerland and Europe. Besides first-class fund solutions and other collective investments, we develop and manage tailor-made infrastructure mandates for qualified investors.
Get to know us personally.
The pharmaceutical industry is currently high on Donald Trump’s list of priorities. He wants more production and jobs in the US, as well as lower drug prices. As a means of exerting pressure, he is threatening to impose price caps and introduce tariffs on drugs. These goals are, of course, contradictory, which is causing even more uncertainty.
The list of new customs measures against Switzerland, published on the night of Swiss National Day on August 1, came as a surprise. The economic impact of the tariffs is significant.
For the first time, a study shows how differently cantons exempt foundations from taxes. Zurich recently liberalized its practice. How is Lucerne reacting?